The information in this press release is intended for investors.

This press release may not be made public, published or distributed, directly or indirectly, in or into the United States of America, Australia, Belarus, Hong Kong, Japan, Canada, New Zealand, Russia, Singapore, South Africa, South Korea, Switzerland or any other jurisdiction where such disclosure, distribution or publication of this press release would be unlawful or require additional registration measure- or other measures. For more information, refer to the section “Important information” at the end of this press release.

Summary of terms for the warrants

Exercise period
16 November 2026 – 30 November 2026

Issue volume
39,863,928 warrants of series TO2, entitling the holders to subscribe for 39,863,928 shares. If all warrants are exercised, the Company will receive approximately SEK 37.9 million before issue costs

Exercise price
SEK 0.95 per share

Last day of trading in warrants of series TO2
26 November 2026

Share capital and dilution
If all warrants of series TO2 are exercised in full for subscription of new shares, the total number of shares in the Company will increase by 39,863,928 shares, from 320,491,623 shares to 360,355,551 shares, and the share capital will increase by SEK 1,220,546.915745, from SEK 9,812,757.588172 to SEK 11,033,304.503917, corresponding to a dilution effect of approximately 11.06 per cent of the total number of shares in the Company.

Please note that warrants not exercised for subscription of shares by 30 November 2026, or alternatively sold by 26 November 2026, will expire worthless. For the warrants not to expire, active subscription of shares or a sale of the warrants is required.

How the warrants are exercised

Nominee-registered warrants (custody account)
Subscription and payment through exercise of the warrants shall be made in accordance with instructions from the respective nominee. Please note that some banks, for administrative reasons, may have an earlier last day for subscription than 30 November. Please contact your nominee for further information.

Directly registered warrants (VP account)
No issue statement or payment instruction will be sent out. Subscription shall be made through simultaneous cash payment in accordance with the instructions on the application form. The warrants will thereafter be replaced by interim shares pending registration with the Swedish Companies Registration Office.

The application form with payment instructions will be available on the Company’s website www.isofolmedical.com.

Outcome and delivery of new shares
The outcome of the exercise of the warrants will be announced by press release around 1 December 2026. Subscribed and paid shares may be registered in the subscriber’s securities account as interim shares until registration of the issue has been completed with the Swedish Companies Registration Office, whereupon the interim shares are automatically converted into shares in Isofol.

Complete terms and conditions for the warrants
The complete terms and conditions for the warrants are available on the Company’s website, www.isofolmedical.com.

Advisers
ABG Sundal Collier AB is acting as financial adviser to the Company, Advokatfirman Vinge KB as legal adviser to the Company and Aqurat Fondkommission as issuing agent in connection with the handling of TO2.

For more information, please contact
Isofol Medical AB (publ)
Petter Segelman Lindqvist, Chief Executive Officer
Email: petter.s.lindqvist@isofolmedical.com
Phone: 0739-60 12 56

Margareta Hagman, Chief Financial Officer
Email: margareta.hagman@isofolmedical.com
Phone: 0738-73 34 18

The information was submitted for publication, through the agency of the contact persons set out above, on 13 November 2026 at 19:00 CET.

About Isofol
Isofol Medical AB (publ) is a clinical stage biotechnology company focused on improving outcomes for patients with severe forms of cancer. The company’s drug candidate arfolitixorin, a next generation folate treatment, is designed to enhance the efficacy of established standard treatments for several types of solid tumors. Arfolitixorin is currently being evaluated in phase Ib/II in colorectal cancer, the world’s third most common cancer, where there is a significant unmet medical need. Isofol is listed on Nasdaq Stockholm.

www.isofolmedical.com

Important information
The information in this press release neither contains nor constitutes an offer to acquire, subscribe for or otherwise trade in shares, warrants or other securities in Isofol. No action has been taken, and no action will be taken, to permit an offer to the public in any jurisdiction other than Sweden.

This press release is not a prospectus within the meaning of the Prospectus Regulation (EU) 2017/1129 (the “Prospectus Regulation”) and has not been approved by any regulatory authority in any jurisdiction. This press release neither identifies nor purports to identify risks (direct or indirect) that may be associated with an investment in shares, warrants or other securities in Isofol. In order for an investor to fully understand the potential risks and benefits associated with the decision to exercise warrants, any investment decision should be made solely on the basis of the information in the prospectus published by the Company on 17 June 2025 (the “Prospectus”). Accordingly, investors are recommended to read the entire Prospectus. This press release constitutes marketing in accordance with Article 2(k) of the Prospectus Regulation.

The information in this press release may not be published, distributed or otherwise made available, directly or indirectly, in or into the United States, Australia, Belarus, Hong Kong, Japan, Canada, New Zealand, Russia, Switzerland, Singapore, South Africa, South Korea or any other jurisdiction where such action would be unlawful, subject to legal restrictions or require measures other than those required under Swedish law. Actions in violation of this instruction may constitute a breach of applicable securities legislation. No shares, warrants or other securities in Isofol have been registered, and no shares, warrants or other securities will be registered, under the United States Securities Act of 1933, as amended from time to time (the “Securities Act”), or the securities legislation of any state or other jurisdiction in the United States, and may not be offered, sold or otherwise transferred, directly or indirectly, in or into the United States, except pursuant to an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in accordance with the securities legislation of the relevant state or other jurisdiction in the United States.

Within the European Economic Area (“EEA”), no offer of shares, warrants or other securities (“Securities”) is made to the public in any country other than Sweden. In other member states of the European Union (“EU”), such an offer of Securities may only be made in accordance with exemptions in the Prospectus Regulation (EU) 2017/1129. In other EEA countries that have implemented the Prospectus Regulation into national law, such an offer of Securities may only be made in accordance with exemptions in the Prospectus Regulation and in accordance with each relevant implementing measure. In other EEA countries that have not implemented the Prospectus Regulation into national law, such an offer of Securities may only be made in accordance with applicable exemptions under national law.

In the United Kingdom, this document, and any other material relating to the securities referred to herein, is distributed only to, and directed only at, and any investment or investment activity to which this document relates is available only to and will be engaged in only with, “qualified investors” (within the meaning of the UK version of Regulation (EU) 2017/1129, which forms part of UK law by virtue of the European Union (Withdrawal) Act 2018) who are (i) persons having professional experience in matters relating to investments who fall within the definition of “investment professionals” in Article 19(5) of the UK Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”); (ii) “high net worth entities” etc. falling within Article 49(2)(a)-(d) of the Order; or (iii) such other persons to whom such investment or investment activity may lawfully be directed under the Order (all such persons together being referred to as “relevant persons”). An investment or investment activity to which this announcement relates is available in the United Kingdom only to relevant persons and will be engaged in only with relevant persons. Persons who are not relevant persons should not take any action on the basis of this document and should not act or rely on it.

This press release may contain certain forward-looking information that reflects the Company’s current view of future events and financial and operational development. Words such as “intends”, “will”, “assesses”, “expects”, “may”, “plans”, “believes”, “estimates” and other expressions that imply indications or predictions regarding future development or trends, and that are not based on historical facts, constitute forward-looking information. Forward-looking information is by its nature associated with both known and unknown risks and uncertainties, as it depends on future events and circumstances. Forward-looking information is not a guarantee of future results or development, and actual outcomes may differ materially from those stated in forward-looking information.

This information, the opinions and the forward-looking statements contained in this press release speak only as of this date and are subject to change without notice. Isofol does not undertake any obligation to publish updates or revisions of forward-looking information, future events or similar circumstances, other than as required by applicable law.

As Isofol conducts operations worthy of protection under the Swedish Act (2023:560) on the Screening of Foreign Direct Investments, certain investments in the Company’s shares may require review by the Inspectorate of Strategic Products. More information about this is available on the Company’s website, www.isofolmedical.com.